NICE Recommends Takhzyro as Preventive Treatment for HAE Attacks
The National Institute for Health and Clinical Excellence (NICE) has recommended Takhzyro (lanadelumb) as a preventive treatment for hereditary angioedema (HAE) attacks in patients 12 and older, under certain conditions. NICE’s final appraisal determination (FAD) states that Takhzyro should be used only if: patients…